Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infections among people who inject drugs in Kuwait: A cross-sectional study

Haya Altawalah 1, Sahar Essa 2, Sayeh Ezzikouri 3, Widad Al-Nakib 2

Affiliations

18 April 2019

-

doi: 10.1038/s41598-019-42810-w

Abstract

Injection drug use (IDU) is one of the most significant risk factors for viral hepatitis (B and C) and human immunodeficiency virus (HIV) infections. This study assessed seroprevalence rates of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in people who inject drugs (PWID) in Kuwait. We conducted a cross-sectional study from April to September 2017. A total of 521 consecutive subjects, admitted at Al-Sabah Hospital. The serological and virological markers of HBV, HCV, and HIV were tested using automated platforms. The mean age of the participants was 32.26 yrs, and the sex ratio (Male/Female) was 15.28. The prevalence rates of HBsAg, anti-HCV, and anti-HIV antibodies were 0.38% (95% CI: 0.07-1.53%), 12.28% (95% CI: 9.65-15.48), and 0.77% (95% CI: 0.25-2.23%), respectively. HCV-RNA was evident in 51.72% (95% CI: 38.34-64.87%) among anti-HCV positive participants. Multivariate analysis showed that the high prevalence of HCV infection amongst PWID is associated with age. Whereas, multivariate analysis revealed no significant associations with age and gender regarding HIV and HBV infections. The results suggest that high rates of HBV, HCV, and HIV infections among injecting drug users than the general population. These findings emphasize the importance of introducing interventions and harm reduction initiatives that have a high impact on reducing needle sharing.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1 HCV-RNA positivity stratified by age among PWID.

Figure 1 HCV-RNA positivity stratified by age among PWID.

Similar articles

Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.

Semá Baltazar C, Boothe M, Kellogg T, Ricardo P, Sathane I, Fazito E, Raymond HF, Temmerman M, Luchters S.BMC Public Health. 2020 Jun 3;20(1):851. doi: 10.1186/s12889-020-09012-w.PMID: 32493347 Free PMC article.

A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators?

Leung J, Peacock A, Colledge S, Grebely J, Cunningham EB, Hickman M, Vickerman P, Stone J, Trickey A, Dumchev K, Lynskey M, Hines L, Griffiths P, Mattick RP, Degenhardt L, Larney S.J Infect Dis. 2019 Jun 5;220(1):78-90. doi: 10.1093/infdis/jiz058.PMID: 30726973 Free PMC article.

High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.

Semá Baltazar C, Horth R, Boothe M, Sathane I, Young P, Chitsondzo Langa D, Condula M, Ricardo H, Dengo Baloi L, Cummings B, Schaad N, Gouveia L, Teodoro E, Raymond HF.BMC Infect Dis. 2019 Dec 2;19(1):1022. doi: 10.1186/s12879-019-4655-2.PMID: 31791273 Free PMC article.

Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.

Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, Lynskey M, Griffiths P, Mattick RP, Hickman M, Larney S.Lancet Glob Health. 2017 Dec;5(12):e1192-e1207. doi: 10.1016/S2214-109X(17)30375-3. Epub 2017 Oct 23.PMID: 29074409 Free PMC article. Review.

Overview of substance abuse and hepatitis C virus infection and co-infections in India.

Basu D.J Neuroimmune Pharmacol. 2010 Dec;5(4):496-506. doi: 10.1007/s11481-010-9227-6. Epub 2010 Jun 19.PMID: 20559752 Review.

Cited by

Prevalence of Hepatitis B Virus infection in the Gulf Cooperation Council: a systematic review and meta-analysis.

Alali AA, Abo-Shehada MN.BMC Infect Dis. 2022 Nov 7;22(1):819. doi: 10.1186/s12879-022-07806-4.PMID: 36344923 Free PMC article.

A Review on the Development of Gold and Silver Nanoparticles-Based Biosensor as a Detection Strategy of Emerging and Pathogenic RNA Virus.

Ibrahim N, Jamaluddin ND, Tan LL, Mohd Yusof NY.Sensors (Basel). 2021 Jul 28;21(15):5114. doi: 10.3390/s21155114.PMID: 34372350 Free PMC article. Review.

Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis.

Rajabi A, Sharafi H, Alavian SM.Harm Reduct J. 2021 Jan 22;18(1):12. doi: 10.1186/s12954-020-00441-9.PMID: 33482831 Free PMC article. Review.

A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran.

Behzadifar M, Behzadifar M, Bragazzi NL.BMC Public Health. 2020 Jan 14;20(1):62. doi: 10.1186/s12889-020-8175-1.PMID: 31937278 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. WHO. In WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO WHO Guidelines Approved by the Guidelines Review Committee (2017).
  2.  
    1. Degenhardt L, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192–e1207. doi: 10.1016/S2214-109X(17)30375-3. - DOI - PMC - PubMed
  3.  
    1. Mumtaz GR, Awad SF, Feizzadeh A, Weiss HA, Abu-Raddad LJ. HIV incidence among people who inject drugs in the Middle East and North Africa: mathematical modelling analysis. J Int AIDS Soc. 2018;21:e25102. doi: 10.1002/jia2.25102. - DOI - PMC - PubMed
  4.  
    1. Edwards G, Arif A, Hadgson R. Nomenclature and classification of drug- and alcohol-related problems: a WHO Memorandum. Bull World Health Organ. 1981;59:225–242. - PMC - PubMed
  5.  
    1. Abdala N, et al. Sexually transmitted infections, sexual risk behaviors and the risk of heterosexual spread of HIV among and beyond IDUs in St. Petersburg, Russia. Eur Addict Res. 2008;14:19–25. doi: 10.1159/000110407. - DOI - PubMed
  6.  
    1. Kamarulzaman A, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet. 2016;388:1115–1126. doi: 10.1016/S0140-6736(16)30769-3. - DOI - PubMed
  7.  
    1. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol. 2000;16:1043–1049. doi: 10.1023/A:1010833917242. - DOI - PubMed
  8.  
    1. Kinkel HT, et al. Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal. PLoS One. 2015;10:e0134455. doi: 10.1371/journal.pone.0134455. - DOI - PMC - PubMed
  9.  
    1. Ramezani A, et al. HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. AIDS Care. 2014;26:1122–1126. doi: 10.1080/09540121.2014.882485. - DOI - PMC - PubMed
  10.  
    1. Zhou YH, et al. Comparison of HIV-, HBV-, HCV- and co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border region. PLoS One. 2011;6:e16349. doi: 10.1371/journal.pone.0016349. - DOI - PMC - PubMed
  11.  
    1. Weissenbacher M, et al. High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clin Infect Dis. 2003;37(Suppl 5):S348–352. doi: 10.1086/377560. - DOI - PubMed
  12.  
    1. Wu J, et al. Infection status and risk factors of HIV, HBV, HCV, and syphilis among drug users in Guangdong, China–a cross-sectional study. BMC Public Health. 2010;10:657. doi: 10.1186/1471-2458-10-657. - DOI - PMC - PubMed
  13.  
    1. Wenz B, et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011–14) BMC Public Health. 2016;16:927. doi: 10.1186/s12889-016-3545-4. - DOI - PMC - PubMed
  14.  
    1. Spada E, et al. Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy. J Urban Health. 2018;95:99–110. doi: 10.1007/s11524-017-0207-5. - DOI - PMC - PubMed
  15.  
    1. Al-Owaish RA, Anwar S, Sharma P, Shah SF. HIV/AIDS prevalence among male patients in Kuwait. Saudi Med J. 2000;21:852–859. - PubMed
  16.  
    1. Factbook, C. W. HIV/AIDS - ADULT PREVALENCE RATE (2018).
  17.  
    1. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis. 2010;14:e28–33. doi: 10.1016/j.ijid.2009.03.002. - DOI - PubMed
  18.  
    1. Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction. 2010;105:311–318. doi: 10.1111/j.1360-0443.2009.02759.x. - DOI - PubMed
  19.  
    1. Kretzschmar M, et al. Regional differences in HIV prevalence among drug users in China: potential for future spread of HIV? BMC Infect Dis. 2008;8:108. doi: 10.1186/1471-2334-8-108. - DOI - PMC - PubMed
  20.  
    1. Zhou YH, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China. PLoS One. 2012;7:e42937. doi: 10.1371/journal.pone.0042937. - DOI - PMC - PubMed
  21.  
    1. Chehadeh W, et al. Hepatitis C virus infection in a population with high incidence of type 2 diabetes: impact on diabetes complications. J Infect Public Health. 2011;4:200–206. doi: 10.1016/j.jiph.2011.05.004. - DOI - PubMed
  22.  
    1. Ameen R, et al. Prevalence of viral markers among first-time Arab blood donors in Kuwait. Transfusion. 2005;45:1973–1980. doi: 10.1111/j.1537-2995.2005.00635.x. - DOI - PubMed
  23.  
    1. Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. Int J Infect Dis. 2016;46:116–125. doi: 10.1016/j.ijid.2016.03.012. - DOI - PubMed
  24.  
    1. al-Fuzae L, Aboolbacker KC, al-Saleh Q. beta-Thalassaemia major in Kuwait. J Trop Pediatr. 1998;44:311–312. doi: 10.1093/tropej/44.5.311. - DOI - PubMed
  25.  
    1. Fraser H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018;68:402–411. doi: 10.1016/j.jhep.2017.10.010. - DOI - PMC - PubMed
  26.  
    1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555. doi: 10.1016/S0140-6736(15)61412-X. - DOI - PubMed

Page Navigation